Ascendis Pharma A/S (FRA:A71)
Germany · Delayed Price · Currency is EUR 181.00
+3.00 (1.69%)
Last updated: Dec 1, 2025, 8:19 AM CET
Ascendis Pharma Employees
Ascendis Pharma had 1,017 employees as of December 31, 2024. The number of employees increased by 138 or 15.70% compared to the previous year.
Employees
1,017
Change (1Y)
138
Growth (1Y)
15.70%
Revenue / Employee
€635,740
Profits / Employee
€229,047
Market Cap
11.08B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1,017 | 138 | 15.70% |
| Dec 31, 2023 | 879 | 82 | 10.29% |
| Jan 1, 2023 | 797 | 158 | 24.73% |
| Dec 31, 2021 | 639 | 157 | 32.57% |
| Dec 31, 2020 | 482 | 152 | 46.06% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Siemens Aktiengesellschaft | 318,000 |
| Deutsche Telekom AG | 198,194 |
| Mercedes-Benz Group AG | 175,264 |
| Bayerische Motoren Werke Aktiengesellschaft | 159,104 |
| Allianz SE | 156,626 |
| SAP SE | 109,121 |
| Siemens Energy AG | 103,000 |
| Deutsche Bank Aktiengesellschaft | 89,753 |
Ascendis Pharma News
- 6 days ago - US FDA extends review of Ascendis Pharma's therapy for children with dwarfism - Reuters
- 6 days ago - Ascendis Announces Extension of FDA Review Period for TransCon CNP (navepegritide) for Children with Achondroplasia - GlobeNewsWire
- 13 days ago - Ascendis Pharma (ASND): Wedbush Reiterates Outperform Rating | ASND Stock News - GuruFocus
- 14 days ago - Ascendis Pharma (ASND) Reports Positive Results from TransCon CNP Trial for Achondroplasia - GuruFocus
- 14 days ago - Results of Pivotal ApproaCH Trial of TransCon® CNP (Navepegritide) in Children with Achondroplasia Published in JAMA Pediatrics - GlobeNewsWire
- 19 days ago - Ascendis Pharma AS (ASND) Q3 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ... - GuruFocus
- 19 days ago - Q3 2025 Ascendis Pharma A/S Earnings Call Transcript - GuruFocus
- 19 days ago - Ascendis Pharma A/S (ASND) Q3 2025 Earnings Call Transcript - Seeking Alpha